Literature DB >> 30831439

Hypothalamic insulin and glucagon-like peptide-1 levels in an animal model of depression and their effect on corticotropin-releasing hormone promoter gene activity in a hypothalamic cell line.

Jan Detka1, Joanna Ślusarczyk2, Anna Kurek2, Mateusz Kucharczyk2, Tomasz Adamus3, Paweł Konieczny3, Marta Kubera2, Agnieszka Basta-Kaim2, Władysław Lasoń2, Bogusława Budziszewska2.   

Abstract

BACKGROUND: In depression, excessive glucocorticoid action may cause maladaptive brain changes, including in the pathways controlling energy metabolism. Insulin and glucagon-like peptide-1 (GLP-1), besides regulation of glucose homeostasis, also possess neurotrophic properties. Current study was aimed at investigating the influence of prenatal stress (PS) on insulin, GLP-1 and their receptor (IR and GLP-1R) levels in the hypothalamus. GLP-1 and GLP-1R were assayed also in the hippocampus and frontal cortex - brain regions mainly affected in depression. The second objective was to determine the influence of exendin-4 and insulin on CRH promoter gene activity in in vitro conditions.
METHODS: Adult male PS rats were subjected to acute stress and/or received orally glucose. Levels of hormones and their receptors were assayed with ELISA method. In vitro studies were performed on mHypoA-2/12 hypothalamic cell line, stably transfected with CRH promoter coupled with luciferase.
RESULTS: PS has reduced GLP-1 and GLP-1R levels, attenuated glucose-induced increase in insulin concentration and increased the amount of phosphorylated IR in the hypothalamus of animals subjected to additional stress stimuli, and also decreased the GLP-1R level in the hippocampus. In vitro studies demonstrated that insulin is capable of increasing CRH promoter activity in the condition of stimulation of the cAMP/PKA pathway in the applied cellular model.
CONCLUSION: Prenatal stress may act as a preconditioning factor, affecting the concentrations of hormones such as insulin and GLP-1 in the hypothalamus in response to adverse stimuli. The decreased GLP-1R level in the hippocampus could be linked with the disturbances in neuronal plasticity.
Copyright © 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Corticotropin-releasing hormone; Depression; Glucagon-like peptide-1; Hypothalamus; Insulin; mHypoA-2/12

Mesh:

Substances:

Year:  2018        PMID: 30831439     DOI: 10.1016/j.pharep.2018.11.001

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  5 in total

1.  Changes in regulators of lipid metabolism in the brain: a study of animal models of depression and hypothyroidism.

Authors:  Katarzyna Głombik; Jan Detka; Magdalena Kukla-Bartoszek; Alicja Maciejska; Bogusława Budziszewska
Journal:  Pharmacol Rep       Date:  2022-08-11       Impact factor: 3.919

2.  The effects of exercise and diet on mental status, insulin signaling pathway, and microbiome in obese mice.

Authors:  Sang-Seo Park; Tae-Woon Kim; Bo-Kyun Kim; Seong-Hyun Kim; Jong-Suk Park; Mal-Soon Shin
Journal:  J Exerc Rehabil       Date:  2022-06-27

3.  Association between GLP-1 receptor gene polymorphisms with reward learning, anhedonia and depression diagnosis.

Authors:  Hale Yapici-Eser; Vivek Appadurai; Candan Yasemin Eren; Dilek Yazici; Chia-Yen Chen; Dost Öngür; Diego A Pizzagalli; Thomas Werge; Mei-Hua Hall
Journal:  Acta Neuropsychiatr       Date:  2020-03-26       Impact factor: 3.403

4.  Analysis of Chronic Mild Stress-Induced Hypothalamic Proteome: Identification of Protein Dysregulations Associated With Vulnerability and Resiliency to Depression or Anxiety.

Authors:  Weibo Gong; Wei Liao; Chui Fang; Yanchen Liu; Hong Xie; Faping Yi; Rongzhong Huang; Lixiang Wang; Jian Zhou
Journal:  Front Mol Neurosci       Date:  2021-03-02       Impact factor: 5.639

Review 5.  Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression.

Authors:  Jan Detka; Katarzyna Głombik
Journal:  Pharmacol Rep       Date:  2021-05-18       Impact factor: 3.024

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.